Skip to Content
UW Health SMPH
American Family Children's Hospital
SHARE TEXT
Douglas G. McNeel, MD, PhD close
Douglas G. McNeel, MD, PhD

Douglas G. McNeel, MD, PhD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. McNeel is a genitourinary medical oncologist with a clinical and research focus on prostate cancer immunology. Since 1997 he and his laboratory have studied vaccines for prostate cancer, specifically identifying antigens to target in vaccines, testing the ability of vaccines to eliminate prostate cancer cells and translating these studies to human clinical trials.

Specialties

Medical Oncology

UW Health Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

Hospital Affiliation(s)

University of Wisconsin Hospital and Clinics (primary)

Languages Spoken

English, French
Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Internal Medicine
Medical Oncology
Fellowship University of Washington School of Medicine, Seattle
Fred Hutchinson Cancer Research Center
Residency University of Washington School of Medicine, Seattle
Internship University of Washington School of Medicine, Seattle
Medical School University of Chicago, Pritzker School of Medicine, Chicago, IL, 1994

Awards/Honors

Best Doctors® in America 2014

Best Doctors® in America 2013

Best Doctors® in America 2011


PubMed Articles
McNeel DG Gardner TA Higano CS Kantoff PW Small EJ Wener MH Sims RB DeVries T Sheikh NA Dreicer R . A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T. Cancer Immunol Res. 2014 Sep 4;
[PubMed ID: 25189164]
McNeel DG Becker JT Eickhoff JC Johnson LE Bradley E Pohlkamp I Staab MJ Liu G Wilding G Olson BM . Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clin Cancer Res. 2014 Jul 15;20(14):3692-704
[PubMed ID: 24850844]
Smith HA Rekoske BT McNeel DG . DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses. Vaccine. 2014 Mar 26;32(15):1707-15
[PubMed ID: 24492013]
Teja Colluru V Johnson LE Olson BM McNeel DG . Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol. 2013 Dec 11;
[PubMed ID: 24332642]
Lang JM Wallace M Becker JT Eickhoff JC Buehring B Binkley N Staab MJ Wilding G Liu G Malkovsky M McNeel DG . A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clin Genitourin Cancer. 2013 Dec;11(4):407-15
[PubMed ID: 23835291]
Casavant BP Mosher R Warrick JW Maccoux LJ Berry SM Becker JT Chen V Lang JM McNeel DG Beebe DJ . A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells. Methods. 2013 Dec 1;64(2):137-43
[PubMed ID: 23806645]
Cetnar J Wilding G McNeel D LoConte NK McFarland TA Eickhoff J Liu G . A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urol Oncol. 2013 May;31(4):436-41
[PubMed ID: 21481618]
Olson BM Johnson LE McNeel DG . The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother. 2013 Mar;62(3):585-96
[PubMed ID: 23108626]
Johnson LE Becker JT Dubovsky JA Olson BM McNeel DG . Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments. Chin Clin Oncol. 2013 Mar 1;2(1)
[PubMed ID: 24324949]
Olson BM McNeel DG . Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Front Oncol. 2013;3:109
[PubMed ID: 23653893]
Becker JT McNeel DG . Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination. J Immunother Cancer. 2013;1:2
[PubMed ID: 24764533]
Olson BM Jankowska-Gan E Becker JT Vignali DA Burlingham WJ McNeel DG . Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol. 2012 Dec 15;189(12):5590-601
[PubMed ID: 23152566]
Bloom JE McNeel DG Olson BM . Vaccination using peptides spanning the SYT-SSX tumor-specific translocation. Expert Rev Vaccines. 2012 Dec;11(12):1401-4
[PubMed ID: 23252384]
Johnson LE Frye TP McNeel DG . Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncoimmunology. 2012 Dec 1;1(9):1546-1556
[PubMed ID: 23264901]
Bruce JY Lang JM McNeel DG Liu G . Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol. 2012 Nov;10(11):716-22
[PubMed ID: 23271258]
McNeel DG Becker JT Johnson LE Olson BM . DNA Vaccines for Prostate Cancer. Curr Cancer Ther Rev. 2012 Nov 1;8(4):254-263
[PubMed ID: 24587772]
Olson BM McNeel DG . Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence. Expert Rev Vaccines. 2012 Nov;11(11):1315-7
[PubMed ID: 23249231]
Morse MD McNeel DG . T cells localized to the androgen-deprived prostate are TH1 and TH17 biased. Prostate. 2012 Aug 1;72(11):1239-47
[PubMed ID: 22213030]
McNeel DG Smith HA Eickhoff JC Lang JM Staab MJ Wilding G Liu G . Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother. 2012 Jul;61(7):1137-47
[PubMed ID: 22210552]
Johnson LE McNeel DG . Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes. Prostate. 2012 May 15;72(7):730-40
[PubMed ID: 22529020]